https://alnylampolicies.com/privacy
Privacy Policy | Alnylam Policies
PRIVACY POLICYLast Updated: 17 November 2023Our privacy policies, statements, and notices offer details about how personal data is processed by Alnylam...
privacy policyalnylampolicies
https://alnylampolicies.com/legal
Legal Notice | Alnylam Policies
LEGAL NOTICE Terms and Conditions of Use Effective Date: November 13, 2019 Please read these terms and conditions of use carefully before reading this web site
legal noticealnylampolicies
https://www.alnylam.com/patients/genetic-testing-and-counseling-program
Genetic Testing & Counseling for Patients | Alnylam
Alnylam Act® provides a no-charge, third-party genetic testing and counseling program. Learn more about speaking to your doctor about eligibility.
genetic testingfor patientscounselingalnylam
https://www.alnylam.com/patients/patient-services
Alnylam Assist® & Patient Services | Alnylam
Learn more about the patient services Alnylam offers, including Alnylam Assist® and Alnylam Act™.
alnylampatientservices
https://www.rnaiscience.com/
Alnylam Medical Information for US Healthcare Professionals | Alnylam RNAi Science - US
us healthcare professionalsmedical informationalnylamrnaiscience
https://www.alnylam.com/
The Leading RNAi Therapeutics Company | Alnylam
Alnylam has pioneered RNAi therapeutics, an innovative approach to gene silencing. We are driven by science and committed to developing transformational...
leadingrnaitherapeuticscompanyalnylam
https://www.alnylam.com/contact-us
Contact Us | Alnylam
For inquiries or to request additional information, Alnylam can be reached by email or by calling the company's corporate headquarters.
contact usalnylam
https://www.alnylam.it/
Home | Alnylam Italy
alnylamitaly
https://www.alnylam.de/
Alnylam® Pharmaceuticals | Deutschland | Alnylam-de
pharmaceuticalsdeutschlandalnylam
https://www.alnylam.jp/
Alnylam® Pharmaceuticals | Alnylam Japan
pharmaceuticalsalnylamjapan
https://business.wapakdailynews.com/wapakdailynews/article/bizwire-2023-7-24-alnylam-announces-partnership-with-roche-to-co-develop-and-co-commercialize-zilebesiran-an-investigational-rnai-therapeutic-for-the-treatment-of-hypertension-in-patients-with-high-cardiovascular-risk
User | wapakdailynews.com - Alnylam Announces Partnership with Roche to Co-Develop and...
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension...
https://www.europharmajobs.com/job_display/281592/Associate_Director_Clinical_Pharmacology_Alnylam_Pharmaceuticals_Maidenhead_Zug_or_Amsterdam_Multiple_Countries
Associate Director, Clinical Pharmacology - Alnylam Pharmaceuticals, Maidenhead, Zug or Amsterdam
Apply for the Associate Director, Clinical Pharmacology Job, Alnylam Pharmaceuticals, Maidenhead, Zug or Amsterdam, Multiple Countries. Pharma Jobs in Europe...
associate directorclinical pharmacologyalnylampharmaceuticalsmaidenhead
https://financialdata.net/stocks/ALNY
ALNYLAM PHARMACEUTICALS, INC. (ALNY, US02043Q1076) - Company Profile
ALNYLAM PHARMACEUTICALS, INC. company profile, charts, statistics, financials, insider trades, institutional holdings, and more.
alnylampharmaceuticalsinccompanyprofile
https://druganalyst.com/Alnylam/Leqvio%20royalties
Leqvio royalties (inclisiran) - Alnylam Sales History and Forecasts - DRUGANALYST
sales historyroyaltiesinclisiranalnylamforecasts
https://www.pharmaindustrial-india.com/news/medison-pharma-and-alnylam-pharmaceuticals-expand-partnership-to-reach-more-patients-globally
Medison Pharma and Alnylam Pharmaceuticals Expand Partnership to Reach More Patients Globally -...
Medison Pharma and Alnylam Pharmaceuticals Expand Partnership to Reach More Patients Globally - Global Pharma
https://www.alnylam.com/contact
Contact | Alnylam
alnylam
https://business.theeveningleader.com/theeveningleader/quote/news?Symbol=NQ%3AALNY&CurrentPage=19
User | theeveningleader.com - Latest News about Alnylam Pharmaceuticals, Inc. - Common Stock...
latest newsabout alnylamuser
https://dutchcaafoundation.nl/11-mei-2024-bijeenkomst-met-alnylam-en-lumc-over-wie-kan-meedoen-aan-het-aln-app-onderzoek-en-waarom/
11 Mei 2024: bijeenkomst met Alnylam en LUMC over wie kan meedoen aan het ALN-APP onderzoek en...
Nov 6, 2024 - De Dutch CAA Foundation zet zich in om de ziekte Cerebrale amyloïd angiopathie (CAA) onder de aandacht te brengen en geld in te zamelen voor onderzoek.
https://www.alnylamconnect.eu/
Therapeutic Areas | Alnylam Connect
Healthcare professionals only: Learn more about Alnylam's therapeutic areas by speaking with an Alnylam representative (by phone, email, video chat, or in...
therapeutic areasalnylamconnect
https://causeconsulting.com/essential_grid/alnylampharmaceuticals/
Alnylam Pharmaceuticals - Cause Consulting
Sep 12, 2023 - Development of ESG framework, strategies, and 3-years of ESG reports
alnylampharmaceuticalscauseconsulting
https://business.wapakdailynews.com/wapakdailynews/quote/news?CurrentPage=8&Symbol=NQ%3AALNY&ChannelType=NEWS
User | wapakdailynews.com - Latest News about Alnylam Pharmaceuticals, Inc. - Common Stock...
latest newsabout alnylamuser
https://oneamyloidosisvoice.com/rcuratenew/alnylam-launches-hereditary-attr-hattr-amyloidosis-campaign-help-shorten-time-diagnosis
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for...
https://stocks-assistant.kreatebots.com/alnylam-pharmaceuticals-inc/2026/q1/chat
ALNYLAM-PHARMACEUTICALS-INC Assistant - 2026 Q1 | Stocks Assistant
Get detailed insights about ALNYLAM-PHARMACEUTICALS-INC for Q1 of 2026.
alnylampharmaceuticalsincassistantstocks
https://www.biospace.com/alnylam-to-webcast-conference-call-discussing-third-quarter-2023-financial-results
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results - BioSpace
Oct 19, 2023 - Alnylam Pharmaceuticals, Inc. announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2,...
conference call
https://pro.kraken.com/app/trade/stocks-alny
ALNY (Alnylam Pharmaceuticals) - Trade Stocks | Kraken Pro
Trade Alnylam Pharmaceuticals (ALNY) on Kraken Pro. Trade stocks alongside crypto with real-time pricing, professional execution, and multi-asset portfolio...
trade stocksalnypharmaceuticalskrakenpro
https://druganalyst.com/Alnylam/Amvuttra
Amvuttra (vutrisiran) - Alnylam Sales History and Forecasts - DRUGANALYST
sales historyalnylamforecasts
https://www.alnylam.com/transparency-italian
Transparency Italian | Alnylam
transparencyitalianalnylam
https://investors.alnylam.com/annual-meetings
Annual Meetings | Alnylam Pharmaceuticals, Inc.
Find information about our annual stockholder meeting and view the previous year's annual report.
annual meetingsalnylampharmaceuticalsinc
https://data.rnaiscience.com/congresses/heart-failure-association-2026?site=us
HFA 2026: Heart Failure Association | Alnylam RNAi Science Data Hall
Heart Failure Association (HFA) 2026 | Barcelona, Spain. View selected Alnylam scientific information presented at HFA 2026. Connect with Alnylam Medical...
heart failurescience datahfaassociationalnylam
https://capella.alnylam.com/2022/10/05/ots-2022
Alnylam Presents at OTS 2022 Annual Meeting - Alnylam
Mar 4, 2024 - We presented on platform and clinical results at the Oligonucleotide Therapeutics Society (OTS) 2022 18th Annual Meeting held in Phoenix, Arizona on October...
alnylampresentsotsannualmeeting
https://www.rnaiscience.com/pipeline-clinical-trials/pipeline/zilebesiran
Zilebesiran for Hypertension (HTN) | Pipeline & Clinical Trials | Alnylam RNAi Science - US
Learn about Zilebesiran, an investigational RNAi therapeutic, and explore ongoing clinical trials from Alnylam in patients with hypertension (HTN), a...
clinical trialszilebesiranhypertensionhtnpipeline
https://www.sprih.com/customers/alnylam-pharmaceuticals/
Alnylam Pharmaceuticals - Sprih
Jun 18, 2025 - How Alnylam Pharmaceuticals streamlined sustainability data, automated audits, and gained full visibility with Sprih.
alnylampharmaceuticals
https://alnylamevents.com/patientevents?id=EM-06099
Patient Events Registration | Alnylam Events
patient eventsregistrationalnylam
https://www.rnaiscience.com/congresses-publications/international-porphyrias-symposium-IPS-2025
International Porphyrias Symposium (IPS) 2025 | Alnylam RNAi Science - US
International Porphyrias Symposium (IPS) 2025 | Washington, D.C. . Please view International Porphyrias Symposium (IPS) 2025 at Washington, D.C. . Connect with...
internationalsymposiumipsalnylamrnai
https://www.cmlviz.com/stocks/ALNY/news/2022/07/26/custom-pre-earnings-bullish-diagonal-trigger-in-alnylam-pharmaceuticals-inc
Custom Pre-earnings Bullish Diagonal Trigger in Alnylam Pharmaceuticals Inc
Jul 26, 2022 - Custom Pre-earnings Bullish Diagonal Trigger in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Earnings.
custompreearningsbullishdiagonal
https://amyloidosisnewstoday.com/news/alnylam-opens-advocacy-for-impact-grants-program-fap-attr-amyloidosis-patient-group-projects/
Alnylam Opens 'Advocacy for Impact' Grant Program Supporting FAP, Like Patient Groups
Dec 3, 2019 - Alnylam is accepting applications by ATTR amyloidosis advocacy groups, and will award up to $50,000 in 2020 to projects that address patients' unmet needs.
impact grant program
https://www.bigmoleculewatch.com/tag/alnylam-v-pfizer/
Alnylam v. Pfizer
Content tagged with Alnylam v. Pfizer.
alnylamvpfizer
https://news.alnylam.com/
Newsroom | Alnylam
Welcome to Alnylam's newsroom where you can find the latest news, insights, perspectives and press releases.
newsroomalnylam
https://business.wapakdailynews.com/wapakdailynews/quote/news?Symbol=NQ%3AALNY
User | wapakdailynews.com - Latest News about Alnylam Pharmaceuticals, Inc. - Common Stock...
latest newsabout alnylamuser
https://www.biospace.com/alnylam-reports-positive-topline-results-from-kardia-1-phase-2-dose-ranging-study-of-zilebesiran-an-investigational-rnai-therapeutic-in-development-to-treat-hypertension-in-patients-at-high-cardiovascular-risk
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran,...
Sep 7, 2023 - Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-1 Phase 2 study of zilebesiran, an...
https://investors.alnylam.com/press-release?id=27761
Alnylam Pharmaceuticals Press Release | Oct 25, 2023 | Alnylam Reports Additional Positive Interim...
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
press releasealnylampharmaceuticalsoct
https://www.agencyx.ie/our-work/alnylam-pharmaceuticals-disease-awareness-campaign/
Digital hATTR Awareness Campaign | Alnylam & Agency X
Targeted storytelling by Agency X raised nationwide recognition of hereditary ATTR amyloidosis, spotlighting its Irish roots and driving empowered...
awareness campaigndigitalalnylamagencyx
https://nl.marketscreener.com/koers/aandeel/ALNYLAM-PHARMACEUTICALS-I-8322/grafieken/
Alnylam Pharmaceuticals, Inc.: Grafische Technische Analyse | ALNY | US02043Q1076 | MarketScreener...
Alnylam Pharmaceuticals, Inc.: Technische analyse met dynamische grafiek en uitgestelde koers Aandeel Alnylam Pharmaceuticals, Inc. | ALNY | Nasdaq
technische analysealnylampharmaceuticalsincgrafische